An interventional study of Collagen, Hyaluronic Acid, Vitamin C, and Manganese and Intra-articular infiltration in Tendinitis of Shoulder, Hyaluronic Acid and Dietary Supplements, sponsored by I.R.C.C.S. Fondazione Santa Lucia. Recruiting at 1 site in Italy. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by I.R.C.C.S. Fondazione Santa Lucia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Shoulder Pain with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Shoulder Pain · Italy.
Among the 13 studies in Shoulder Pain with a site in Italy, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, and was the 6th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →5 of the 13 studies in Shoulder Pain with a site in Italy are open now. Recruiting first, the newest first:
University of Trieste · Sites in Italy
Ages 17–30 · Healthy volunteers
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18+
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 30–70
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2012; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 590 interventional studies indexed under Shoulder Pain.
Median enrollment 50 across the 11 interventional studies, 80 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
I.R.C.C.S. Fondazione Santa Lucia is the lead sponsor of 56 studies on the registry; 16 are open to participants now.
I.R.C.C.S. Fondazione Santa Lucia has 1 study filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Shoulder Pain with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123805Fondazione IRCCS Policlinico San Matteo di PaviaACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Shoulder Pain with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study aims to investigate the effectiveness of oral supplementation with a nutraceutical containing Collagen, Hyaluronic Acid, Vitamin C, and Manganese in functional outcome and pain reduction in cases of shoulder rotator cuff tendinopathy compared to a cycle of intra-articular hyaluronic acid injections.
The project involves the recruitment of 50 adult individuals presenting with shoulder pain and instrumental evidence of rotator cuff tendinopathy. All participants will receive one intra-articular injection of 1 ml of triamcinolone acetonide 40 mg. After the injection, participants will be divided into two groups according to Good Clinical Practice guidelines. One group will begin taking one vial per day for 56 days of an oral supplement containing Hyaluronic Acid, Collagen, Vitamin C, and Manganese (HA-COL) (Tendogenial®, B2Pharma) starting from the day following enrollment (Group 1). The other group will undergo a cycle of 3 intra-articular injections with hyaluronic acid (HA) (Hyalotend®, Fidia) (Group 2).
The hypothesis is that oral supplementation with HA-COL may have the same efficacy as intra-articular hyaluronic acid treatment in reducing pain and improving shoulder functionality.
Functional assessments will be conducted by a clinician unaware of the participants' group assignment. The following assessment scales will be used:
Numeric Rating Scale (NRS) for pain (from 0 to 10), evaluating 3 aspects of pain: 1) pain at rest, 2) nocturnal pain, 3) pain during movement.
Shoulder Disability Questionnaire (SDQ) for functionality.
Assessments will be conducted at the following time points:
T0) Before the administration of corticosteroid intra-articular injection (baseline).
T1) Seven days after the start of HA-COL intake for Group 1 and before the first intra-articular HA injection for Group 2 (T1, seven days from T0).
T2) At mid-cycle of oral HA-COL supplementation for Group 1 (28 days of intake) and seven days after the last HA injection for Group 2 (T2, 21 days from T1).
T3) Follow-up at 28 days from T2, at the end of the 56-day oral treatment cycle for Group 1, and 28 days after the last injection for Group 2 (T3, 56 days from T0).
Background Shoulder pain is a prevalent symptom primarily affecting the adult population, with an incidence of approximately 19 per 1000 and a prevalence ranging from 7 to 26%, particularly affecting women. The primary cause of shoulder pain is rotator cuff pathology, characterized by nocturnal pain and weakness, especially during external rotation and elevation movements of the shoulder, attributable to excessive loading on the cuff tissues. These symptoms often result in disability and functional impairment.
The etiology of rotator cuff pathology appears multifactorial, often associated with chronic age-related degeneration characterized by a reduced ability to synthesize collagen, increased levels of free radicals, and heightened catabolic activity (5). Tendinopathies exhibit widespread structural changes, including increased apoptosis of tenocytes, collagen fiber disintegration leading to a decrease in collagen type I, an increase in collagen type III resulting in a reversal of the collagen I/III ratio, and ineffective neoangiogenesis.
As tendinopathy primarily represents a degenerative condition where the inflammatory component plays a minor role, current therapeutic strategies mainly focus on regenerative approaches. While intra-articular cortisone therapy has historically been utilized to alleviate pain from rotator cuff injuries, its potential detrimental effect on tendon collagen limits its long-term efficacy, rendering cortisone therapy beneficial only in the short term.
Conversely, intra-articular treatment with hyaluronic acid (HA) for rotator cuff injuries appears promising in reducing pain and improving shoulder function. A recent review analyzed 11 studies encompassing a total of 1102 patients. Low to medium molecular weight hyaluronic acids were utilized in these studies, with infiltration performed either via anatomical landmarks or ultrasound guidance, targeting either intra-articular or subacromial sites. Moreover, rare minor side effects (such as pain at the injection site or slight vagal effects) were reported, with no instances of allergic reactions.
Hyaluronic acid (HA) is a carbohydrate, specifically a mucopolysaccharide, naturally present in all living organisms. When unbound to other molecules, it binds to water, imparting a rigid viscous 'jelly-like' quality. HA serves as an integral component of synovial fluid, crucial for joint chondroprotection, and constitutes a significant portion of the tendon extracellular matrix.
Upon injection into a joint, HA diminishes cytokine-induced responses and reduces synovial inflammation, ultimately relieving pain and enhancing joint function. Notably, preclinical in vitro and in vivo studies have demonstrated that exogenous peritendinous HA possesses the ability to inhibit fibroblast activity and diminish the proinflammatory M1 activation state of macrophages.
Observations of improved lubrication, chondroprotection, and enhanced synovial fluid characteristics have also been reported. Additionally, HA facilitates tenocyte regeneration, modulates the ratio of collagen type I/III, and mitigates apoptosis and impaired angiogenesis.
It is important to note that in most studies, HA was not injected directly into the degenerated tendon but rather near and/or into the joint space. While it can be speculated that alterations in synovial fluid may positively impact the tendon itself, it remains plausible that clinical improvement could be secondary to the favorable effects on concomitant arthrosis frequently associated with the condition.
Rationale for Dietary Supplementation of Collagen and HA:
Tendons primarily comprise cells, predominantly tenoblasts along with endothelial cells and some chondrocytes, as well as proteoglycans, notably decorin and hyaluronic acid, and collagen, primarily type I. The tendon exhibits a highly organized extracellular matrix wherein collagen molecules assemble into filamentous collagen fibrils (formed by microfibrils), which further aggregate to constitute collagen fibers, the principal structural components.
Various reviews have assessed the effectiveness of oral collagen supplementation in enhancing tendon structure. Particularly, a review highlights that some studies have demonstrated promising clinical implications of collagen peptide supplementation in the prevention and treatment of tendinopathies, although conclusive evidence is still lacking. Another review indicates that collagen supplementation alongside physical training significantly influences pain relief, increased cross-sectional area, and tendon thickness . From a joint perspective, collagen supplementation enhances mobility and functionality while reducing pain.
Oral supplementation of hyaluronic acid has predominantly been investigated for its effects on joints. For instance, it has been found effective in ameliorating pain and enhancing the quality of life in patients with knee arthrosis, with sustained effects observed at 2 months . Furthermore, the combined administration of HA and collagen orally has shown to improve functional recovery in patients following anterior cruciate ligament reconstruction, with evidence from resonance imaging indicating improved neoligament maturation.
Experimental design In order to conduct this study, we will recruit 50 patients with rotator cuff injuries from the outpatient clinic of the Santa Lucia Foundation. A physiatrist from the clinic, participating in the project, will explain the study to the enrolled individuals and obtain their informed consent.
The enrolled patients will undergo infiltrative treatment with corticosteroids (Triamcinolone acetonide 40 mg, 1 vial - Kenacort®, BRISTOL-MYERS SQUIBB S.r.l.).
The enrolled patients will be randomized in 2 groups: oral supplements (Group 1 - G1) or intra-articular hyaluronic acid (Group 2 - G2).
The Experimental Group (G1) will begin taking a supplement called Tendogenial® (B2Pharma S.r.l.) the day after enrollment. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese. Each day for 28 days, participants in G1 will consume one vial of Tendogenial®.
Group 2 (G2) will receive three intra-articular injections of Hyalotend® (Fidia), a viscous solution of sodium salt hyaluronic acid (500-730 kDa) obtained by bacterial fermentation in buffered saline. The injections will be administered without ultrasound guidance, using pre-filled 20 mg/2 ml syringes. The route of administration will be intra-articular via the posterior access route.
Participants will be advised to take only paracetamol as needed for pain relief. Additionally, they will be instructed not to undergo physiotherapy during the study period. Any participants who undergo physiotherapy or receive other analgesic therapies during the study will be excluded from the statistical analysis.
Inclusion Criteria:
Persistent shoulder pain lasting for at least 2 months, unresponsive to conservative treatment (nonsteroidal anti-inflammatory drugs [NSAIDs] and rehabilitation).
Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture.
Limited active range of motion (ROM) in the shoulder. Age between 30 and 80 years. Willingness to provide informed consent to participate in the study.
Exclusion Criteria:
Traumatic shoulder injury as the cause of pain. History of shoulder dislocation, fracture, or previous shoulder surgery. Presence of signs indicating ligamentous instability. Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis. Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months.
Diagnosis of rheumatic or neoplastic diseases. Ongoing therapy with anticoagulants. Cervical radiculopathy. Pregnancy. History of heart, kidney, or liver failure. Cognitive impairment.
Both study groups will undergo assessment using pain and functional scales by a clinician who is blinded to the treatment group.
In addition to providing informed consent to participate in the study, participants will also sign a consent form specifically for infiltration, prepared by the Santa Lucia Foundation. Any adverse reactions or side effects experienced by participants will be documented and reported.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assumption of 1 vial/day starting from the day after enrollment for 56 days. This supplement contains Collagen, Hyaluronic Acid, Vitamin C, and Manganese.
Dietary Supplement: Collagen, Hyaluronic Acid, Vitamin C, and Manganese
Intra-articular injections of a viscous solution of sodium salt hyaluronic acid (500-730 kDa) in pre-filled 20 mg/2 ml syringes, 1/week for 3 weeks.
Drug: Intra-articular infiltration
The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
Also known as: Tendogenial
Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Also known as: Hyalotend
Numeric rating scale (NRS)
Change from baseline NRS at 1 weeks and at 4 weeks and at 8 weeks. NRS is a 10-point scale grading the pain at rest, during movement and during night-time
Time frame: 1) (T0 - baseline). 2) Before the first administration of intra-articular HA for Group 2 and at seven days from the initiation of HA-COL for Group 1 (T1, seven days from T0). 3) At seven days fo
Shoulder Disability Questionnaire (SDQ) for shoulder functionality
Change from baseline SDQ at 1 weeks and at 4 weeks and at 8 weeks. The SDQ is a self-assessment scale comprising 22 items designed to gauge functional limitations in daily activities and participation in social engagements among patients with shoulder disorders. Each item requires a YES/NO response, with YES scored as 1. A higher total score (up to 22) indicates greater disability attributed to the shoulder pathology
Time frame: 1) (T0 - baseline). 2) Before the first administration of intra-articular HA for Group 2 and at seven days from the initiation of HA-COL for Group 1 (T1, seven days from T0). 3) At seven days fo
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 5 years following article publication
Access criteria: Proposals should be directed to the personal corrisponding author's mail address.
Started Aug 2024 (actual). Primary completion is estimated for Nov 2025, 14 months after the start.
Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 14 months is above that.
Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I.R.C.C.S. Fondazione Santa Lucia